Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
Hyehyun JeongKyu-Pyo KimJae Ho JungDae Wook HwangJae-Hoon LeeKi Hun KimDeok Bog MoonMyung Ah LeeSe Jun ParkHong Jae ChonJin-Hong ParkJi Sung LeeBaek-Yeol RyooChanghoon YooPublished in: Hepatology (Baltimore, Md.) (2023)
In resected lymph node-positive extrahepatic cholangiocarcinoma, adjuvant GemCis did not improve survival outcomes compared with capecitabine.